NCT04550663

NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors

One-center, Open-label, Single-arm Clinical Study of the Safety and Effectiveness of NKG2D CAR-T Cells Infusion in the Treatment of Relapsed/ Refractory NKG2DL+ Tumors

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.

Detailed description

In this study,the enrollment of the patients must meet the inclusion and exclusion criteria . All subjects will be asked to continue to undergo long-term gene safety follow-up.

Conditions

• Solid Tumor
• Hepatocellular Carcinoma
• Colorectal Cancer
• Glioma

Interventions

Type	Name	Description
DRUG	KD-025 CAR-T cells	Autologous genetically modified anti-NKG2DLs CAR transduced T cells

Timeline

• Start date: 2020-09-25
• Primary completion: 2022-09-25
• Completion: 2023-03-25
• First posted: 2020-09-16
• Last updated: 2020-09-23

Locations

1 site across 1 country: China